Inventera Inc
0007J0
Company Profile
Business description
Inventera Inc is engaged in research and development of nanomedicines applicable to the diagnostic and therapeutic fields, based on original nanostructure platform technology. Invinity, company's nanostructure platform technology is a biocompatible nanodrug delivery system that simultaneously improves in vivo dispersion stability and target delivery efficiency. It is a platform technology with scalability that can be combined with various active ingredients, including not only MRI contrast agents but also therapeutic small molecule drugs and antibody-drug conjugates.
Contact
111 Seocho-daero
2nd floor
Bangbae-dong, Seocho-gu
Seoul
KORT: +82 25331102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
16
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,200.65 | 63.22 | -0.77% |
| DAX 40 | 23,779.42 | 301.21 | -1.25% |
| Dow JONES (US) | 47,909.92 | 1,325.46 | 2.85% |
| FTSE 100 | 10,574.80 | 34.08 | -0.32% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,634.99 | 617.14 | 2.80% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,782.81 | 165.96 | 2.51% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |